Home › Research › Topics › serum
serum
14 studies tagged serum, dated 2009-12-01 to 2025-07-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Equivalence of Plasma and Serum for Clinical Measurement of p-tau217: Comparative Analyses of Four Blood-Based Assays 2025-07-01
- Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer's disease of different severity 2023-09-07
- Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL-F/NL-F knock-in mouse model of Alzheimer's disease 2023-03-25
Studies
14 studies carry this tag.
Date range
2009 to 2025
Top journals
- BMC neurology 2
- PloS one 2
- Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 2
- Alzheimer's research & therapy 1
- Annals of clinical and translational neurology 1
11 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Phosphorylated tau (p-tau) 217 is a promising blood biomarker for Alzheimer's disease (AD).
-
Serum C5a level increased with AD severity, and its expression was positively correlated with serum pro-inflammatory factor levels, and negatively correlated with cognitive function.
-
Our findings suggest a temporal sequence of events in App NL-F/NL-F knock-in mice, in which initial deposition of Aβ aggregates in the brain is followed by a decline of the Aβ42/Aβ40 ratio in CSF and serum once the cerebral Aβ pathology becomes significant.
-
The MMSE score, MoCA score, serum miR-27a-3p level, cerebrospinal fluid miR-27a-3p, Aβ42 levels and Aβ42/Aβ40 ratio of AD patients in mild group and moderate-to-severe group were all lower than those in the control group, and the moderate-to-severe group were lower than the mild group (all P < 0.05);the serum NEAT1 level, SUVR, and cerebrospinal fluid NEAT1 and BACE1 levels were higher than those in the control group, and the moderate-to-severe group were higher than the mild group (all P < 0.05).
-
Alzheimer's disease (AD) is the most common neurodegenerative disease in the older adults.
-
Insufficient amyloid marker test repeatability may result either from imperfection of the used laboratorial techniques or inadequate selection of control groups with their comorbidities.
-
50/100
This study is the first to find protective associations of serum ApoB with CSF AD core biomarkers, especially in SCD individuals.
-
Serum levels also correlated strongly with CSF levels for Simoa-based measurements (both ϱ = 0.62).
-
In the diagnosis of Alzheimer's disease (AD) total tau (T-tau), tau phosphorylated at threonine 181 (P-tau181), and the 42 amino acid isoform of alpha β-amyloid (Aβ) are well established surrogate CSF markers.
-
We identified the feasibility of a blood-based biomarker approach in AD diagnostics though the results warrant validation in large-scale studies.
-
The results, specifically that lower serum IGF-I was associated with cognitive impairment, suggest that metabolism of IGF-I may be involved in the pathogenesis of cognitive deficits in Alzheimer's disease.
-
Serum NGAL levels are increased in DS and associated with distinct species of Aβ depending on the progression of dementia as diagnosed by baseline and follow-up clinical assessments.
-
Based on the hypothesis that tau is cleaved proteolytically and then released into the blood, we here provide evidence for the presence of an ADAM10-generated tau fragment (Tau-A) in serum.
-
Serum Abeta40/42 ratio was significantly higher in MDD patients than in controls, and this difference was seen for both elderly and young subjects.